Federico Garrido
Overview
Explore the profile of Federico Garrido including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
3533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39428126
Background: Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to...
2.
Aptsiauri N, Garrido F
Clin Cancer Res
. 2022 Jul;
28(23):5021-5029.
PMID: 35861868
HLA class I molecules are key in tumor recognition and T cell-mediated elimination. Loss of tumor HLA class I expression with different underlying molecular defects results in reduced antigen presentation...
3.
Garrido M, Perea F, Vilchez J, Rodriguez T, Anderson P, Garrido F, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680201
Total or partial loss of class I antigens reduce the recognition of specific tumor peptides by cytotoxic T lymphocytes favoring cancer immune escape during natural tumor evolution. These alterations can...
4.
Gutierrez-Bautista J, Rodriguez-Nicolas A, Rosales-Castillo A, Lopez-Ruz M, Martin-Casares A, Fernandez-Rubiales A, et al.
J Microbiol Immunol Infect
. 2021 Sep;
55(3):421-427.
PMID: 34475005
Background: Human leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules...
5.
Gil-Julio H, Perea F, Rodriguez-Nicolas A, Cozar J, Gonzalez-Ramirez A, Concha A, et al.
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34298868
Cancer eradication and clinical outcome of immunotherapy depend on tumor cell immunogenicity, including HLA class I (HLA-I) and PD-L1 expression on malignant cells, and on the characteristics of the tumor...
6.
Algarra I, Garrido F, Garcia-Lora A
Cancer Metastasis Rev
. 2021 Apr;
40(2):501-517.
PMID: 33860434
In recent years, immunotherapy has proven to be an effective treatment against cancer. Cytotoxic T lymphocytes perform an important role in this anti-tumor immune response, recognizing cancer cells as foreign,...
7.
Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F
Cell Mol Immunol
. 2021 Jan;
18(3):556-565.
PMID: 33473191
T cell-mediated immune therapies have emerged as a promising treatment modality in different malignancies including colorectal cancer (CRC). However, only a fraction of patients currently respond to treatment. Understanding the...
8.
Gutierrez-Bautista J, Rodriguez-Nicolas A, Rosales-Castillo A, Jimenez P, Garrido F, Anderson P, et al.
Front Immunol
. 2020 Dec;
11:596553.
PMID: 33324414
The severity of SARS-CoV-2 infection has been related to uncontrolled inflammatory innate responses and impaired adaptive immune responses mostly due to exhausted T lymphocytes and lymphopenia. In this work we...
9.
Pulido M, Chamorro V, Romero I, Algarra I, S-Montalvo A, Collado A, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32545680
The capacity of cytotoxic-T lymphocytes to recognize and destroy tumor cells depends on the surface expression by tumor cells of MHC class I molecules loaded with tumor antigen peptides. Loss...
10.
Montes P, Bernal M, Campo L, Gonzalez-Ramirez A, Jimenez P, Garrido P, et al.
Cancer Immunol Immunother
. 2019 Nov;
68(12):2015-2027.
PMID: 31705171
The transformation and progression of myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia (sAML) involve genetic, epigenetic, and microenvironmental factors. Driver mutations have emerged as valuable markers for defining risk...